Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ACAT2 is acetyl-CoA acetyltransferase 2. The human ACAT2 gene is located at 12q13.3-q15 and consists of 15 exons and 13 introns. The full length is about 18 kb. All exon/intron junction sequences are classical GT/AG sequences. ACAT2 is mainly distributed in the hepatocytes and the top of the epithelial cells of the small intestine. It catalyzes the connection of cholesterol with long-chain fatty acids to form cholesterol esters, which plays an important role in the absorption, transportation, and storage of cholesterol in the body.
Figure 1. The protein–protein interactions of ACTA2 and other lipid metabolism enzymes or proteins. (Zhao, et al. 2015).
In liver and small intestinal cells, ACAT2 is involved in lipoprotein assembly. The role of ACAT2 in hepatocytes is to protect cells from excess cholesterol. ACAT2 catalyzes the synthesis of cholesterol esters and triacylglycerols, which are transported by microsomal triglyceride transporters to apolipoprotein B, followed by cholesterol, phospholipids and other apolipoproteins assemble into very low-density lipoproteins that are secreted from the liver into the bloodstream.
Some researchers used antisense oligonucleotide technology to knock down the ACAT2 gene in mouse liver and found that inhibiting liver ACAT2 activity can reduce the production of cholesterol esters in the liver and apolipoprotein B and the secretion of lipoprotein (very low-density lipoprotein, medium-density, and low-density lipoproteins), and high-density lipoprotein levels remain unchanged. At the same time, it was found that the excretion of neutral sterols in the intestine increased and the sterols excreted in the bile remained unchanged. This reveals the esterification pathway of cholesterol in the liver and its excretion pathway, that is, excretion by the intestine rather than bile excretion. ACAT2 in small intestinal cells esterifies cholesterol to maintain a low concentration of free cholesterol to facilitate the diffusion of cholesterol from the intestinal lumen into cells. Guo et al found that ACAT2 expression in human leukocytes controls the excretion of cholesterol/sterol ester (CE/SE)-containing lipoproteins. Excretion of lipoproteins containing ACAT2-catalyzed CS/SE can avoid cytotoxicity by reducing excess intracellular cholesterol/sterols (especially various oxysterols), which plays an important role in the metabolism of human leukocytes.
He et al. found two human ACAT2 gene polymorphisms, 41A>G (Glu(14)Gly, rs9658625) and 734C>T (Thr(254)IIe, rs2272296)have significant an effect on plasma lipid levels and coronary artery disease by case-control association studies. The results of the study showed that the enzyme activity of the mutant Glu(14)Gly was about two times higher than that of the wild type, and this increase was mainly caused by an increase in the expression and/or stability of the mutant ACAT2 protein. Therefore, the genetic variation of Glu(14)Gly is functionally important and may contribute to the expression and stability of the ACAT2 protein.
ACAT2 and Atherosclerosis
ACAT is an important enzyme that regulates the balance of cholesterol concentrations in plasma and bile. Excessive cholesterol in the plasma leads to atherosclerosis, and an increase in cholesterol secretion in the bile can cause cholesterol stones. A large number of studies at home and abroad have shown that ACAT plays a crucial role in the pathogenesis of atherosclerosis. The most direct and powerful evidence comes from gene knockout experiments. The researchers found that ACAT2-/- mice had decreased cholesterol-absorbing capacity and reduced blood cholesterol levels, as well as for gallstone disease and food-induced hypercholesterolemia in mice with ACAT2 gene knockout (ACAT2-/-). Therefore, it is speculated that specific inhibition of ACAT1 will disrupt the intracellular cholesterol metabolism balance, leading to the cytotoxic effect of cholesterol and not conducive to the prevention of atherosclerosis. Specific inhibition of ACAT2 expression and activity will reduce cholesterol absorption and transport. Moreover, it does not affect the balance of intracellular cholesterol metabolism. It is an effective target and promising treatment measures for preventing hyperlipidemia and atherosclerosis.
ACAT2 and Tumor
Studies have shown that prostate cancer is an androgen-dependent disease and is associated with high cholesterol levels. By studying the activity and expression of ACAT in cholesterol metabolism of prostate cancer LNCaP and PC-3 cell lines, it was found that in PAR+ cells, the expression of androgen receptor and ACAT1 protein decreased, cholesterol level decreased, and the expression of ACAT2 remained unchanged. This reveals the importance of regulation of cholesterol metabolism in prostate cancer cells.
In addition, in adult liver, hepatocyte nuclear factor (HNF1α) is a trans-acting factor of the liver-specific ACAT2 gene. When combined with a site on the ACAT2 gene, it can significantly up-regulate the expression of ACAT2 in the liver. LBL laboratory using human liver tissue, liver cancer, and adjacent tissues, combined with a variety of human liver cell lines, showed that human liver cell line, liver tissue, liver cancer and paracancerous tissues all expressed HNF1α. The expression of Cdx2 and ACAT2 wasn't observed in human normal liver cell line LO2 and liver tissue. In the tumor cell line HepG2, both Cdx2 and ACAT2 were expressed. In 50% of patients with liver cancer, the results of adjacent tissues were consistent with those of normal liver cell line LO2 and liver tissue. The results of cancer tissue detection were consistent with the above-mentioned tumor cell line HepG2, indicating that the expression of ACAT2 gene in liver cancer is closely related to the high expression of Cdx2.
These findings not only clarify the molecular mechanism of hepatocyte tissue-specific expression of ACAT2 gene for the first time but also suggest that ACAT2 can be used as a new potential biomarker molecule for detecting liver cancer. Huang et al. found that ACAT2 may affect cancer progression by activating leptin receptor through analyzing tissue samples from primary breast cancer. The data suggest that leptin may enhance the proliferation, migration, and invasion of breast cancer cells through up-regulation of ACAT2. Therefore, the leptin/ACAT2 axis may be a therapeutic target for breast cancer, especially in postmenopausal and/or obese women.
Reference:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.